Acadia Pharmaceuticals (ACAD) EBIAT (2016 - 2025)
Historic EBIAT for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $71.8 million.
- Acadia Pharmaceuticals' EBIAT rose 11907.22% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 10323.88%. This contributed to the annual value of $226.5 million for FY2024, which is 46949.87% up from last year.
- Acadia Pharmaceuticals' EBIAT amounted to $71.8 million in Q3 2025, which was up 11907.22% from $26.7 million recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' EBIAT registered a high of $143.7 million during Q4 2024, and its lowest value of -$113.1 million during Q1 2022.
- For the 5-year period, Acadia Pharmaceuticals' EBIAT averaged around -$5.3 million, with its median value being -$14.5 million (2021).
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 13976.75% in 2023, then soared by 289721.72% in 2024.
- Over the past 5 years, Acadia Pharmaceuticals' EBIAT (Quarter) stood at -$43.1 million in 2021, then grew by 3.18% to -$41.7 million in 2022, then soared by 209.76% to $45.8 million in 2023, then soared by 213.87% to $143.7 million in 2024, then crashed by 50.06% to $71.8 million in 2025.
- Its EBIAT was $71.8 million in Q3 2025, compared to $26.7 million in Q2 2025 and $19.0 million in Q1 2025.